Daily close, T-120 (7/31/24) through T+5. Run-up high $960.02 on 9/6/24, low $727.2 on 11/22/24 (T-120 to T-1). FDA decision 1/15/25. Historical price action, not a forecast.
Positioning before the decision
On Dec 6, 2024, 14 days before the decision date, at-the-money options priced a move of ±6.3% through Dec 27, 2024 (the first listed expiry after the decision; ATM implied volatility 33%). The stock closed +1.3% at the first close across the decision and +3.4% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for Omvoh (mirikizumab-mrkz) on January 15, 2025. The primary source is linked on this page.
What was Omvoh (mirikizumab-mrkz) under FDA review for?
The application covered Inflammatory bowel disease (IBD). The FDA approved the application on January 15, 2025.
How did LLY stock react to the FDA decision?
On the decision day LLY moved +0.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.